Black men who were identified as sexual minorities were more receptive to long-acting injectable pre-exposure prophylaxis ...

In Philadelphia, the leading causes of death are heart disease, cancer, and unintentional drug overdose. While some of these ...

The same tools that companies use to sell products can be used to encourage people to get vaccinated, get a colonoscopy or ...

Another company, ViiV Healthcare, brought a PrEP injection to market in 2021, but it only lasts two months, and remains little used. If two shots a year offered the same protection, Das knew, it ...

Increased PrEP usage is linked to decreased HIV diagnosis rates, with a notable decline from 13.0 to 10.6 per 100,000 over a decade. State-level PrEP coverage significantly impacts HIV diagnosis rates ...

With the FDA’s much-anticipated nod for Gilead Sciences’ long-acting HIV pre-exposure prophylaxis (PrEP) injection Yeztugo (lenacapavir), a new era of HIV prevention has dawned. | The FDA signed off ...

HIV-1 negative study participants (median age, 21 years; 99.9% Black) were randomly assigned 2:2:1 to receive twice-yearly subcutaneous lenacapavir (n=2134), once daily Descovy (emtricitabine and ...

In PrEP, patients regularly take one pill every day. There is also an event-driven PrEP, where patients take two pills of PrEP between two and 24 hours before they anticipate having sex. But it's ...

In 2012, the FDA approved Truvada, also made by Gilead Sciences, making it the first PrEP medication for HIV prevention in uninfected adults in the United States – but “even though PrEP has ...

Yeztugo demonstrated superiority over Truvada in reducing the risk of incident HIV-1 infections. The Food and Drug Administration (FDA) has approved Yeztugo ® (lenacapavir) for pre-exposure ...

Yeztugo (lenacapavir) will be the first option that gives people who need or want PrEP the option of injecting only twice a ...